Directory
>
Dongxing Zha
Dongxing Zha
CTO, TCR Discovery and Engineering at Alloy Therapeutics | Founder and CEO at Keyway TCR Discovery | Alloy Therapeutics, Inc.
Waltham, Massachusetts, United States
Dongxing Zha
Summary
Dongxing Zha is a distinguished leader in drug development, specializing in immune-oncology and biologics. As the CTO at Alloy Therapeutics and the founder of Keyway TCR Discovery, he drives innovative research aimed at creating effective anti-cancer therapies. His leadership of the ORBIT platform at MD Anderson Cancer Center showcases his commitment to collaborative science and patient-centered drug development. With a rich academic background, including a PhD in Microbiology, Dongxing has a proven track record in biotechnology, specifically in antibody development and cellular therapies. He has held significant roles at prestigious institutions like Merck and the Chinese Academy of Sciences, reflecting his deep expertise in life sciences and molecular biology. Dongxing's work not only advances scientific understanding but also aims to translate discoveries into real-world applications for cancer treatment.
Dongxing Zha
Work Experience
CTO, TCR Discovery and Engineering at Alloy Therapeutics | Founder and CEO at Keyway TCR Discovery at
Alloy Therapeutics, Inc.
September 2021 - Present
Institute Head, ORBIT Platform at
The University of Texas M D Anderson Cancer Center
June 2019 - August 2021
Institute Associate Director at
The University of Texas M D Anderson Cancer Center
September 2017 - June 2019
Institute Group Leader at
The University of Texas M D Anderson Cancer Center
May 2014 - August 2017
Research Fellow and Group Leader at
Merck
May 2006 - May 2014
Senior Research Scientist at
GlycoFi
September 2002 - May 2006
Postdoctoral Fellow at
Max-Planck-Institut fur Kohlenforschung
May 1999 - September 2002
Research Scientist at
Novo Nordisk
January 1998 - May 1999
Scientist at
Chinese Academy Of Sciences
January 1997 - January 1998
Dongxing Zha
Education
Huazhong Agricultural University, Doctor Of Philosophy - Phd
Anhui Normal University , Bachelor Of Science - Bs
Frequently Asked Questions about Dongxing Zha
What is Dongxing Zha email address?
Dongxing Zha's primary email address is ************@alloytx.com. To view the full verified email and additional contact details, sign up for free with Muraena.
What company does Dongxing Zha work for?
Dongxing Zha is a CTO, TCR Discovery and Engineering at Alloy Therapeutics | Founder and CEO at Keyway TCR Discovery at Alloy Therapeutics, Inc., a company specializing in Commercial physical research.
Where Dongxing Zha graduated from?
Dongxing Zha holds a degree in Microbiology, General from Huazhong Agricultural University.
How can I directly contact Dongxing Zha?
To contact Dongxing Zha directly, you can use the email address ************@alloytx.com. Complete contact information is available upon registration with Muraena.
Is Dongxing Zha an immigrant?
Yes, Dongxing Zha is an immigrant and currently based in United States
Who is Dongxing Zha?
Dongxing Zha is a distinguished leader in drug development, specializing in immune-oncology and biologics. As the CTO at Alloy Therapeutics and the founder of Keyway TCR Discovery, he drives innovative research aimed at creating effective anti-cancer therapies. His leadership of the ORBIT platform at MD Anderson Cancer Center showcases his commitment to collaborative science and patient-centered drug development. With a rich academic background, including a PhD in Microbiology, Dongxing has a proven track record in biotechnology, specifically in antibody development and cellular therapies. He has held significant roles at prestigious institutions like Merck and the Chinese Academy of Sciences, reflecting his deep expertise in life sciences and molecular biology. Dongxing's work not only advances scientific understanding but also aims to translate discoveries into real-world applications for cancer treatment.
Dongxing`s contact details
************@alloytx.com
****@mdanderson.org
Colleagues
General Partner
Vice President of Daedamab Business Development
Harvard Business Review Advisory Council Member
Senior Vice President Therapeutic Discovery Strategies
VP Head of Protein Science & Bioanalytics